

**MARYLAND INSURANCE ADMINISTRATION
SEPTEMBER 25, 2017
PHARMACEUTICAL SERVICES WORKGROUP
MEETING 3 AGENDA**

I. Opening Remarks – Refining our search for common ground?

II. Next Meeting (#4)

Tuesday, October 23, 2017

1 to 4PM

MIA Hearing Room, 24th Floor

200 St. Paul Place

Baltimore, MD 21202

III. Specialty Drugs

- 1) Should the definition of Specialty Drug be amended, specifically at § 15-847(a)(5)(ii) to recognize a higher cost than \$600 for a 30 day supply?
 - a. Is \$1,000 high enough to make an impact?
 - b. Is \$2,500 too high?
 - c. What are the impacts, if any, on premiums if the \$600 amount is raised?

- 2) What accreditation organizations other than URAC are there for specialty pharmacy?
 - a. Joint Commission Accreditation , Accreditation Commission for Health Care, Community Health Accreditation Program, Center for Pharmacy Practice Accreditation (CPPA)
 - b. Which if any of these other accreditations are potentially acceptable to Carriers, Plans, and Pharmacy Benefit Managers?
 - c. What are the negatives or perceived issues with the other accreditations?

IV. Wrap Up